key: cord-0855055-8eyx269r
authors: Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad
title: Can COVID-19 vaccines improve cardiovascular outcomes?
date: 2022-04-29
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2022.102350
sha: cd0e47322010dc10c5a50580a47ac652c4a6ba3f
doc_id: 855055
cord_uid: 8eyx269r

Thus far, the investigations on the efficacy of the COVID-19 vaccines in randomized trials [8,9] have been centered around reducing the risk of severe infection and mortality. We opine those investigations on the efficacy of the COVID-19 vaccines to reduce the risk of cardiovascular outcomes should be performed to understand if COVID-19 vaccination has cardiovascular benefits. Such investigations could also develop more confidence toward the acceptance of COVID-19 vaccines, especially when some of the COVID-19 vaccines (particularly the mRNA vaccines such as BNT162b2 and mRNA-1273 vaccines) have been associated with the rare occurrence of cardiovascular complications, including myocarditis and pericarditis [10,11]. While the infrequency and the mild nature of the myocarditis and pericarditis cases after vaccination greatly exceed the small increased risk, specious reports on social media are still fueling the COVID-19 vaccine hesitancy. Therefore, we urge the performance of prospective investigations to establish the relationship between COVID-19 vaccines and cardiovascular outcomes.

We congratulate Diaz-Arocutipa et al. [1] for their insightful systematic review and meta-analysis of randomized controlled trials which evaluated the efficacy of the influenza vaccine on cardiovascular outcomes in patients with coronary artery disease. As mentioned by the authors, influenza infection is associated with a myriad of cardiovascular manifestations, including thrombotic events, myocarditis, pericarditis, acute decompensated heart failure, arrhythmias, and sudden cardiac death. Indeed, since influenza infection is a predisposing factor for atherosclerosis, it can also trigger the occurrence of acute coronary syndromes. Therefore, the systematic review and meta-analysis by Diaz-Arocutipa et al. [1] , reported that influenza vaccination significantly reduced the risk of major adverse cardiovascular events (pooled relative risk = 0.63; 95% confidence interval 0.51 to 0.77 and cardiovascular mortality (relative risk = 0.53; 95% confidence interval 0.38 to 0.74), can serve as a reminder for the clinicians about the importance of influenza vaccination as secondary prevention for acute cardiovascular events.

The findings of the systematic review and meta-analysis by Diaz-Arocutipa et al. [1] have made us wonder if similar investigations can be replicated to shed some light on the efficacy of the COVID-19 vaccines to reduce the risk of cardiovascular outcomes, considering that coronavirus disease 2019 (COVID-19) cases still soaring around the globe. As with influenza infection, patients with acute COVID-19 may present with a broad spectrum of clinical cardiac presentations. For instance, as detected by troponin elevation, myocardial injury is commonly identified in patients hospitalized with COVID-19 [2] . In addition, patients with COVID-19 also have a heightened risk of developing myocarditis [3] and Takotsubo cardiomyopathy [4] . Moreover, studies [5, 6] have also suggested that COVID-19 increases the risk of developing acute coronary syndromes. For example, in one study [5] , there was an increased risk of acute myocardial infarction in patients with COVID-19 compared to non-infected controls (adjusted odds ratio = 1.22; 95% confidence interval 1.08 to 1.38). Indeed, the increased risk of cardiovascular diseases extends beyond the acute phase of COVID-19, in which at one-year after COVID-19, patients still manifested an increased risk of developing major adverse cardiovascular events [7] .

Thus far, the investigations on the efficacy of the COVID-19 vaccines in randomized trials [8, 9] have been centered around reducing the risk of severe infection and mortality. We opine those investigations on the efficacy of the COVID-19 vaccines to reduce the risk of cardiovascular outcomes should be performed to understand if COVID-19 vaccination has cardiovascular benefits. Such investigations could also develop more confidence toward the acceptance of COVID-19 vaccines, especially when some of the COVID-19 vaccines (particularly the mRNA vaccines such as BNT162b2 and mRNA-1273 vaccines) have been associated with the rare occurrence of cardiovascular complications, including myocarditis and J o u r n a l P r e -p r o o f pericarditis [10, 11] . While the infrequency and the mild nature of the myocarditis and pericarditis cases after vaccination greatly exceed the small increased risk, specious reports on social media are still fueling the COVID-19 vaccine hesitancy. Therefore, we urge the performance of prospective investigations to establish the relationship between COVID-19 vaccines and cardiovascular outcomes.

Declarations Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated. 

Influenza vaccine improves cardiovascular outcomes in patients with coronary artery disease: A systematic review and metaanalysis

COVID-19 and the Incidence of Acute Myocardial Injury

The importance of myocarditis in Covid-19

Characteristics of Takotsubo cardiomyopathy in patients with COVID-19: Systematic scoping review

Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Long-term cardiovascular outcomes of COVID-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From

Myocarditis and Pericarditis After Vaccination for COVID-19